Lori Guill, in Salem, KY - Speech-Language Pathologist

Lori Guill, is a Speech-language Pathologist based in Salem, Kentucky. Lori Guill is licensed to practice in Kentucky (license number 139826) and her current practice location is 508 N Hayden Ave, Salem, Kentucky. She can be reached at her office (for appointments etc.) via phone at (270) 988-4572.

NPI number for Lori Guill is 1073162475 and her current mailing address is 775 River Rd, Smithland, Kentucky. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1073162475.

Contact Information

	Lori Guill,
	508 N Hayden Ave, Salem, KY 42078-8008
	(270) 988-4572
	Not Available

Healthcare Provider's Profile

Full Name	Lori Guill
Gender	Female
Speciality	Speech-language Pathologist
Location	508 N Hayden Ave, Salem, Kentucky
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1073162475
Provider Enumeration Date: 09/09/2019
Last Update Date: 09/09/2019

Medical Identifiers

Medical identifiers for Lori Guill such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1073162475	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
235Z00000X	Speech-language Pathologist	139826 (Kentucky)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Lori Guill is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Lori Guill, 775 River Rd, Smithland, KY 42081-9427 Ph: () -	Lori Guill, 508 N Hayden Ave, Salem, KY 42078-8008 Ph: (270) 988-4572

News Archive

Scientists identify gene that could predict breast cancer patients' response to tamoxifen

Scientists have identified a gene which could help predict whether a breast cancer patient will respond to taking tamoxifen. The study, published in the British Journal of Cancer today (Wednesday), showed a potential link between the activity of a gene called BCAR4 and the likelihood that a breast cancer tumour will not respond to tamoxifen - widely used to treat women with breast cancer.

AcelRx Pharmaceuticals initiates ARX-04 Phase 3 study in emergency room patients with acute pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute and breakthrough pain, today announced the initiation of an open-label Phase 3 study (SAP302) of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury.

Sunitinib may be associated with cardiac toxicity

Another FDA-approved targeted cancer drug, sunitinib (SutentTM, Pfizer), may be associated with cardiac toxicity, report researchers at Children's Hospital Boston, Dana-Farber Cancer Institute (Boston), and Thomas Jefferson University (Philadelphia).

Michel Kazatchkine to focus on improving partnerships, health care infrastructures

Michel Kazatchkine - France's global ambassador for HIV/AIDS and communicable diseases who on Thursday was selected to be the new executive director of the Global Fund To Fight AIDS, Tuberculosis and Malaria - has announced that he will aim to improve the organization's partnerships with United Nations organizations and donors, the Boston Globe reports.

UL professor awarded HRB grant to improve understanding of Acute Kidney Injury

It is estimated that at least 1 in 5 hospitalised adults develop Acute Kidney Injury (AKI). Emerging evidence suggests that AKI: is under-recognised in clinical practice; predicts an accelerated risk of end-stage kidney disease (ESKD), and may be a risk amplifier for many other chronic diseases with death rates in excess of 20%.

Lori Guill, - Speech-Language Pathologist in Salem, KY